Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Birchtech Q1 2026 Earnings Call - $16.4M Capital Raise Fuels Water Expansion as Air Business Shifts to Recurring Supply
Birchtech delivered a solid first quarter, driven by a strategic pivot from one-time licensing fees to recurring product supply in its mature Air business. The company raised $16.4 million through an ...
- Birchtech raised $16.4 million gross proceeds in February 2026 through a concurrent public offering and uplisting to the NYSE American, increasing cash to $14.7 million with no debt.
- Q1 2026 revenues reached $4.2 million, a 32% increase year-over-year, driven by growth in both Water Treatment and Air product supply.
- The Air business generated $3.5 million in revenue, with a strategic shift from one-time licensing fees to recurring activated carbon product supply as utilities adopt sorbent formulations.
- +7 more takeaways
Bionano Genomics Q1 2026 Earnings Call - Record Flow Cell Sales and Reimbursement Milestones Drive Profitability Push
Bionano Genomics delivered a record Q1 2026 with flow cell sales up 17% year-over-year to 8,178 units, signaling strong demand despite supply constraints. The company’s strategic pivot toward profitab...
- Record Q1 flow cell sales of 8,178 units, up 17% year-over-year, with 21% growth from existing customers after removing new system sales.
- Consumable revenue surged 20% to $3.9 million, reflecting successful strategy shift toward routine users and recurring revenue streams.
- Gross margins expanded to 49.9% in Q1, up from 46% in Q1 2025, driven by operational efficiencies and higher-margin product mix.
- +7 more takeaways
Precipio Diagnostics Q1 2026 Earnings Call - Commercial Pipeline Surges to $10M Amid Margin Pressure and Reimbursement Headwinds
Precipio Diagnostics reported flat Q1 2026 revenue of $6.71 million, a quarter where external reimbursement shifts and commercial investments temporarily obscured underlying momentum. The pathology se...
- Q1 2026 total revenue held flat at $6.71 million year-over-year, up over 30% from Q1 2025, driven by a 36% increase in pathology services to $6.0 million.
- Pathology revenue faced an 8% CMS fee schedule reduction on flow cytometry, resulting in a $500,000 revenue write-down and a $125,000 gross profit hit.
- Product revenue declined $80,000 sequentially to $660,000, primarily due to a single customer shifting an order from late Q1 to early Q2, a timing shift rather than a loss of demand.
- +9 more takeaways
Brookfield Asset Management Q1 2026 Earnings Call - Record Fundraising and Oaktree Integration Drive Strategic Momentum
Brookfield Asset Management delivered a strong first quarter in 2026, with fee-related earnings rising 11% to $772 million and distributable earnings up 7% to $702 million. The firm raised $21 billion...
- Fee-related earnings rose 11% to $772 million, and distributable earnings grew 7% to $702 million, reflecting steady revenue growth and stable margins near 57-58%.
- Brookfield raised $21 billion in Q1, with year-to-date fundraising reaching $67 billion, positioning the firm for a record fundraising year in 2026.
- The Oaktree acquisition is on track to close in Q2, creating a combined credit platform with significant revenue synergies, cost efficiencies, and enhanced ability to serve large institutional clients.
- +7 more takeaways
GlobalFoundries Q1 2026 Earnings Call - Margin Expansion and Optical Networking Momentum Drive Record Profitability
GlobalFoundries delivered a strong first quarter 2026, with revenue of $1.634 billion at the high end of guidance and record gross margins expanding 510 basis points year-over-year to 29%. The results...
- Revenue of $1.634 billion, down 11% sequentially but up 3.1% year-over-year, landing at the high end of guidance.
- Gross margin reached a record 29%, expanding 510 basis points year-over-year, with the largest YoY improvement in three years.
- Communications infrastructure and data center revenue grew 32% year-over-year, with silicon photonics on track to double in 2026.
- +7 more takeaways
Balchem Corporation Q1 2026 Earnings Call - Record Sales and EBITDA Driven by Human Nutrition and Specialty Products
Balchem Corporation kicked off 2026 with a standout first quarter, posting record consolidated sales of $271 million, up 8.1% year-over-year, and record adjusted EBITDA of $74 million, up 12.1%. The g...
- Record Q1 2026 consolidated sales of $271 million, up 8.1% year-over-year, driven by strength across all three segments.
- Record adjusted EBITDA of $74 million, up 12.1%, marking the 27th consecutive quarter of year-over-year growth in adjusted EBITDA.
- Human Nutrition and Health segment sales rose 8.3% to $172 million, fueled by strong demand for minerals, nutrients, and better-for-you food ingredients.
- +7 more takeaways
Investcorp Credit Management BDC Q1 2026 Earnings Call - BDC Shrinks Portfolio Amid Strategic Review and Fee Waivers
Investcorp Credit Management BDC is in a holding pattern. The board has formed a special committee to evaluate strategic alternatives, and the company is actively downsizing its balance sheet to prese...
- The board has formed a special committee of independent directors to evaluate strategic alternatives aimed at maximizing shareholder value, and the company will not take questions during this call.
- Net assets declined 14% sequentially to $52.7 million, with net asset value per share dropping to $2.65 from $4.25 at the end of the prior quarter.
- The investment advisor voluntarily waived 56% of base management fees, saving the company approximately $456,000 in the first quarter.
- +9 more takeaways
National Vision Holdings Q1 2026 Earnings Call - Reaffirming Guidance Amidst Digital Transition and Premiumization Momentum
National Vision delivered a solid Q1 2026, with revenue up 6.6% and adjusted EPS rising to $0.45. The company is successfully shifting its customer mix toward more profitable managed care and progress...
- Q1 2026 net revenue grew 6.6% to $544 million, with adjusted comparable store sales up 4.5% and adjusted EPS increasing to $0.45 from $0.34 year-over-year.
- Average ticket surged 5.1%, driven by a strategic shift toward premium frames and lenses, proving that growth is coming from mix rather than just pricing.
- The company is intentionally shifting its customer mix toward managed care and progressive lens users, who are more profitable and insulated from macro volatility than cash-pay customers.
- +7 more takeaways
Dynatrace FY2026 Earnings Call - ARR Surpasses $2B as Agentic AI Drives Platform Consolidation
Dynatrace delivered a decisive finish to fiscal 2026, crossing the $2 billion ARR threshold and posting 16% growth for a fourth consecutive quarter. The company is no longer just monitoring systems; i...
- ARR exceeded $2 billion, marking a major milestone and sustaining 16% year-over-year growth for four straight quarters.
- Net new ARR grew 12% for the full year, with Q4 constant-currency net new ARR near the high end of guidance at $81 million.
- The Dynatrace Platform Subscription (DPS) model now accounts for over 75% of ARR and 60% of customers, driving higher consumption and deeper platform penetration.
- +7 more takeaways
Kornit Digital Q1 2026 Earnings Call - MATRIX Launch and AIC Growth Drive Momentum
Kornit Digital reported a strong Q1 2026, with revenue of $48.5 million at the high end of guidance and a 12% year-over-year growth in impressions, signaling robust system utilization. The company's s...
- Kornit Digital reported Q1 2026 revenue of $48.5 million, at the high end of guidance, reflecting strong execution and market demand.
- Impressions grew 12% year-over-year on a trailing 12-month basis, driven by higher system utilization and the shift from screen to digital printing.
- 40% of system sales in Q1 came from new customers, with 65% targeting traditional screen printing environments, indicating successful market penetration.
- +7 more takeaways